Western Blot: BAP1 Antibody (1G8) [NB110-60521] - Detection of BAP1 in HeLa WCE.
Flow Cytometry: BAP1 Antibody (1G8) [NB110-60521] - Intracellular flow cytometric staining of 1 x 10^6 CHO (A) and HEK-293 (B) cells using BAP1 antibody (dark blue). Isotype control shown in orange. An antibody ...read more
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Tris-Glycine and 0.15M NaCl
0.05% Sodium Azide
Protein G purified
Western Blot 2 ug/ml
Flow Cytometry 1 ug per million cells
This BAP1 antibody is useful for Western blot. In Western blot a band is seen at ~85 kDa, representing the BAP1 protein.
The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
85 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Read Publication using NB110-60521 in the following applications:
BAP1 (BRCA1-associated protein 1) was initially identified as BRCA1 binding protein and subsequently it was found to be a nuclear deubiquitinating enzyme belonging to ubiquitin C-terminal hydrolase family that play a key role in chromatin by mediating deubiquitination of histone H2A and HCFC1. BAP1 forms the catalytic component of PR-DUB complex (BAP1 and ASXL1) that specifically mediates deubiquitination of histone H2A monoubiquitinated at 'Lys-119' (H2AK119ub1). BAP1 regulates cell growth by mediating deubiquitination of HCFC1 N- and C-terminal chains, with some specificity toward 'Lys-48'-linked polyubiquitin chains compared to 'Lys-63'-linked polyubiquitin chains. BAP1 interferes with activity of BRCA1-BARD1 heterodimer by inhibiting their ability to mediate ubiquitination/autoubiquitination. BAP1 is considered a tumour suppressor and defects in BAP1 gene have been linked to tumor predisposition syndrome (TPDS). Germline mutations of BAP1 confers increased susceptibility for certain malignancies including uveal melanoma, epithelioid atypical Spitz tumours, cutaneous melanoma, and mesothelioma. Somatic BAP1 mutations are linked to cutaneous melanocytic tumours, uveal melanoma, mesothelioma, clear cell renal cell carcinoma etc.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.